Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Avalo Reports 2023 Financial Results and Provides Business Updates